Biology and Management of Salivary Gland Cancers

被引：103

作者：

Adelstein, David J. ^{[1
]}

Koyfman, Shlomo A. ^{[2
]}

El-Naggar, Adel K. ^{[3
,4
]}

Hanna, Ehab Y. ^{[4
]}

机构：

[1] Cleveland Clin, Taussig Canc Inst, Dept Solid Tumor Oncol, Cleveland, OH 44195 USA

[2] Cleveland Clin, Taussig Canc Inst, Dept Radiat Oncol, Cleveland, OH 44195 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA

来源：

SEMINARS IN RADIATION ONCOLOGY | 2012年 / 22卷 / 03期

关键词：

ADENOID CYSTIC CARCINOMA; POSTOPERATIVE RADIATION-THERAPY; PHASE-II TRIAL; MALIGNANT-TUMORS; DUCT CARCINOMA; CONCURRENT CHEMORADIOTHERAPY; MUCOEPIDERMOID CARCINOMA; PHOTON IRRADIATION; ANDROGEN RECEPTOR; PAROTID-GLAND;

D O I：

10.1016/j.semradonc.2012.03.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The salivary gland cancers are uncommon neoplasms of the head and neck, which exhibit considerable pathologic, biological, and clinical diversity. Surgical resection, often with postoperative radiation, is the standard therapeutic approach, and the results after treatment vary widely depending on the tumor histology. Chemotherapy has been of only limited palliative benefit in patients with advanced disease, and there has been little exploration of its use in definitive management. Recent investigation has focused on identification of the characteristic molecular signatures and genomic alterations of the specific histologic subtypes. These efforts have suggested the potential for molecularly targeted therapies, and clinical trials exploring this approach are currently underway. © 2012 Elsevier Inc.

引用

页码：245 / 253

页数：9